Cedirogant (ABBV-157) is an orally bioavailable, small molecule inverse agonist of the retinoid-related orphan receptor gammat (RORgammat). It is utilized in preclinical and clinical research for autoimmune conditions like psoriasis, investigating its mechanism and efficacy in modulating IL-17-driven inflammatory pathways.